Clinical Trials Logo
  1. Home
  2. mCRPC
  3. NCT03851640

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

mCRPC Clinical Trial

Official title:
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Failed Treatments With Abiraterone Acetate and Docetaxel.

Clinical Trial Summary

The study primary objective is to evaluate the effect of HC-1119 soft capsules versus placebo on overall survival (OS) in mCRPC patients who have failed or become intolerant to the treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03851640
Study type Interventional
Source Hinova Pharmaceuticals Inc.
Contact Zhonghua Zhou, Master
Phone +862885058465
Email zhzhou1@hinovapharma.com
Status Recruiting
Phase Phase 3
Start date April 12, 2019
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05383079 - Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT06056791 - Study of INKmune in Patients With mCRPC (CaRe Prostate) Phase 1/Phase 2
Enrolling by invitation NCT04145375 - Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol Phase 1/Phase 2
Recruiting NCT04729114 - Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT02266745 - A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts Phase 2
Recruiting NCT05413850 - Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection Phase 1/Phase 2
Recruiting NCT05340374 - Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01818986 - Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Phase 2
Not yet recruiting NCT04822961 - Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment Phase 2
Active, not recruiting NCT03395197 - Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC Phase 3
Recruiting NCT05547061 - A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy Phase 1/Phase 2